Your session is about to expire
← Back to Search
OTX-TKI for Diabetic Retinopathy
Study Summary
This trial will test a new drug to treat non-proliferative diabetic retinopathy, looking at its safety, tolerability, and effectiveness.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am 18 years old or older.The center of your eye is thicker than 320 micrometers.My eye condition has worsened in the past 6 months, affecting my central vision.I have swelling near the center of my retina.My eye condition is classified as moderately severe to severe non-proliferative diabetic retinopathy.I have diabetes.Your vision in the study eye is at least 20/40 or better.
- Group 1: OTX-TKI
- Group 2: Sham
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this research endeavor have any available enrollment slots?
"The information found on clinicaltrials.gov suggests that this research-based endeavour is presently enlisting trial subjects. This study was initially posted on the 15th of January, 2023 and its details were recently refreshed in mid-February."
To what degree is OTX-TKI deleterious to individuals?
"Due to the limited clinical evidence, our team has assigned OTX-TKI a safety rating of 1 on the scale of 1 to 3. This indicates that it is currently in a Phase 1 trial and more data needs to be collected regarding its efficacy."
How many participants have been recruited for this research endeavor?
"Affirmative. According to the clinicaltrials.gov, this research initiative which was announced on January 15th 2023 is presently recruiting participants. 21 individuals are required across two locations for completion of the study."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger